Hana Pharm Q1 2026: Revenue 62.2B, Operating Profit 7.1B – Strong Results
-
Revenue 62.2B KRW (+8.3% YoY)
-
Operating profit 7.1B KRW (+26.8% YoY)
-
Net income 10.0B KRW (+138% YoY)
-
Additional treasury stock disposal (123,460 shares via block deal); remaining shares for employee compensation
-
Tax penalty 7.44B already paid, preventive measures implemented
-
New factory construction (Pyeongtaek) ongoing, R&D expense 6.1B
-
New drug pipeline: P-CAB in Phase 1, HN61001 global license agreement
KOSPI Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: Hana Pharm (293480)
-
Submission: Hana Pharm. Co., Ltd.
-
Receipt: 05-15-2026